Search
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalIt is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalIt functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".
Fibrinolysin
go.drugbank.com/drugs/DB05254InvestigationalThe combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. … Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.
Bimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug
Micafungin
go.drugbank.com/drugs/DB01141ApprovedInvestigationalIt belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Products: MYCAMINE POWDER FOR SOLUTION FOR INFUSION 50MG/VIALVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigationalVamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigational[A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.